

Tablica 11.1. Prvih 30 lijekova prema financijskoj potrošnji izraženo u eurima u 2025. godini, na teret HZZO-a

RBR	ATK	INN	UKUPNI IZNOS (EUR)
1	L01FF02	pembrolizumab	110.815.787
2	L01FC01	daratumumab	30.922.946
3	L02BB04	enzalutamid	26.498.379
4	L01FG01	bevacizumab	22.728.370
5	L01FY01	pertuzumab i trastuzumab	22.277.048
6	L04AG08	okrelizumab	21.272.030
7	L01FF01	nivolumab	20.888.215
8	V06DX03	namirnice za enteralnu primjenu	18.846.582
9	L01FF05	atezolizumab	18.674.260
10	A10BJ06	semaglutid	16.559.584
11	L01EL01	ibrutinib	16.447.374
12	B05AA01	albumin, ljudski	16.115.549
13	L04AX04	lenalidomid	15.854.567
14	J06BA02	imunoglobulini, humani, za i.v. primjenu	15.759.247
15	A02BC02	pantoprazol	14.927.657
16	L04AB02	infliksimab	14.366.937
17	C09DX04	valsartan i sakubitril	13.725.823
18	L04AB04	adalimumab	13.517.726
19	B01AF02	apiksaban	12.938.901
20	B01AF01	rivaroksaban	12.462.711
21	L01EB04	osimertinib	12.399.918
22	L01EF02	ribociklib	12.376.670
23	M09AX10	risdiplam	11.854.622
24	L01FF03	durvalumab	11.648.160
25	C09BX01	perindopril, amlodipin i indapamid	11.582.584
26	R07AX32	ivakaftor, tezakaftor i eleksakaftor	11.527.208
27	C10AA05	atorvastatin	11.371.450
28	A10BK01	dapagliflozin	11.158.585
29	L03AA13	pegfilgrastim	11.044.486
30	N05AX13	paliperidon	10.950.438